EU Approval For Movetis' Resolor Validates Its Targeted Strategy in GI Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
The Belgian GI specialist's approval for its lead constipation drug illustrates the virtues of seeking out smaller, more targeted patient populations.